Figures computed from official regulatory filings — .
Analysttarget 571.39 USD (+13%) · consensus 4.34/5 · 26 buy · 4 hold · 2 sell
Ownershipinsiders 0.21% · institutions 97.95% · short 2.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for VERTEX PHARMACEUTICALS INC / MA only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
57 buys3,923 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| van Grunsven Jasper | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ambrose Kristen | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SACHS BRUCE Itrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tatsis Ourania | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sachdev Amit | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SACHS BRUCE Itrack record | AwardD (derivative) | $47.5K | SEC |
| Garber Alan M | AwardD (derivative) | $15K | Unusual size | SEC |
| Tatsis Ourania | Sell | $787.5K | SEC |
| McKechnie Duncan | Sell | $799.8K | Unusual size | SEC |
| Liu Joy | Sell | $416.2K | SEC |
| Bozic Carmen | Sell | $287.6K | SEC |
| Bozic Carmen | Sell | $471.4K | SEC |
| Bozic Carmen | Sell | $1.8M | SEC |
| Bozic Carmen | Sell | $785.3K | SEC |
| Liu Joy | Sell | $364.2K | SEC |
| Bozic Carmen | Sell | $888.3K | SEC |
| Bunnage Mark E. | Sell | $15K | SEC |
| Bozic Carmen | Sell | $614K | SEC |
| Bozic Carmen | Sell | $3.1M | Unusual size | SEC |
| Bhatia Sangeeta N. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garber Alan M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MCKENZIE DIANA | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Schneider Jennifer | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thornberry Nancy | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARNEY LLOYDtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |